OverviewSuggest Edit

AroCell AB is an in vitro diagnostics company focusing on the monitoring of hematological malignancies, breast cancer, and other solid tumors. It is involved in the development, manufacture, and sale of products for the measurement of human Thymidine Kinase 1 (TK1) concentration in blood.
TypePublic
Founded2003
HQUppsala, SE
Websitearocell.com

Latest Updates

Share Price (Oct 2021)KR1.5
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at AroCell

Karin Eriksson-Widblom

Karin Eriksson-Widblom

Director
Peter Löwendahl

Peter Löwendahl

Senior Director Regulatory Affairs Director
Eva Nordström

Eva Nordström

Director
Michael Brobjer

Michael Brobjer

CEO
Gunnar Steineck

Gunnar Steineck

CMO
Alona Nyberg

Alona Nyberg

Marketing Director
Show more

AroCell Office Locations

AroCell has an office in Uppsala
Uppsala, SE (HQ)
Virdings allé 32B
Show all (1)

AroCell Financials and Metrics

AroCell Revenue

Market capitalization (20-Oct-2021)

110.5m

Closing stock price (20-Oct-2021)

1.5
AroCell's current market capitalization is kr110.5 m.
Show all financial metrics

AroCell Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

AroCell Online and Social Media Presence

Embed Graph

AroCell Blogs

AroCell’s updated strategy after the merger with IDL Biotech

AroCell AB informs about the company's updated operational strategy following the acquisition of IDL Biotech AB. AroCell has now conducted a review of the overall operations to determine the strategy for the merged company. The company has established a joint office in Bromma, Sweden, so that the op…

AroCell AB (publ) Interim Report January 1st to June 30th, 2021

A word from the CEO”In July, AroCell AB acquired IDL Biotech AB, which develops and markets diagnostic tests for healthcare […] The post AroCell AB (publ) Interim Report January 1st to June 30th, 2021 appeared first on Arocell TK 210 ELISA.

Elevated levels of serum TK1 in Hodgkin Lymphoma patients

AroCell announces today that a new publication titled “Serum concentration of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma” is now available in the scientific journal Upsala Journal of Medical Science. The post Elevated levels of serum TK1 in Hodgk…

New patent application – on serum TK1 levels for prediction of cancer relapse

AroCell AB announced today that a patent application has been filed in the US relating to the measurement of thymidine kinase 1 (TK1), and in particular to the prediction of cancer relapse based on measured serum TK1 levels. The post New patent application – on serum TK1 levels for prediction of can…

AroCell informs about FDA feedback regarding 510(k) application

AroCell announced today that after discussion with the FDA, concluded that the predicate device chosen for AroCell's 510(k) application is not possible given the intended use. This means that the 510(k) route is not applicable for this 510(k) application. Based on this new information from FDA, AroC…

IDL Biotech AB publishes interim report April 1st to June 30th 2021

The post IDL Biotech AB publishes interim report April 1st to June 30th 2021 appeared first on Arocell TK 210 ELISA.
Show more

AroCell Frequently Asked Questions

  • When was AroCell founded?

    AroCell was founded in 2003.

  • Who are AroCell key executives?

    AroCell's key executives are Karin Eriksson-Widblom, Peter Löwendahl and Eva Nordström.

  • Who are AroCell competitors?

    Competitors of AroCell include Agena Bioscience, EDP Biotech and Preora Healthcare.

  • Where is AroCell headquarters?

    AroCell headquarters is located at Virdings allé 32B, Uppsala.

  • Where are AroCell offices?

    AroCell has an office in Uppsala.

  • How many offices does AroCell have?

    AroCell has 1 office.